Novartis | NOVN - Kewajiban Lancar





Kewajiban Lancar Perubahan Tanggal
AbbVie USD 43.29B 3.9B 2025-12
Alcon AG USD 3.05B 59M 2025-12
Almirall EUR 350.64M 52.12M 2025-12
Amgen USD 24.96B 534M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
Autolus Therapeutics Ltd USD 73.44M 9.63M 2025-12
Bayer EUR 32.58B 3.63B 2025-12
Biogen USD 3B 350.5M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Fresenius EUR 9.56B 1.27B 2025-09
Fresenius Medical Care EUR 6.25B 485.68M 2025-12
Galapagos EUR 152.86M 213.7M 2025-12
Genmab DKK 1.43B 686M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
GRIFOLS EUR 2.02B 135.85M 2025-12
Hikma Pharmaceutical USD 1.45B 603M 2025-12
J&J USD 57.72B 3.59B 2026-03
Lonza CHF 3.57B 421M 2025-12
Merck EUR 9.04B 405M 2025-12
Merck USD 28.33B 301M 2025-12
Novartis USD 27.28B 4.72B 2025-12
Novartis USD 27.28B 4.72B 2025-12
Novo Nordisk DKK 215.66B 18.7B 2025-12
Orion EUR 798.6M 238.3M 2026-03
Pfizer USD 36.6B 1.13B 2025-09
Philips EUR 7.51B 479M 2025-12
Recordati EUR 1.04B 24.44M 2025-09
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 30.01B 1.66B 2026-03
UCB EUR 4.4B 470M 2025-12